Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use PARSABIV safely and effectively. See full prescribing information for PARSABIV. PARSABIV® (etelcalcetide) injection, for intravenous use Initial U.S. Approval: 2017
Medication labelWhy this: Advisory · dailymed-prescription
PARSABIV is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Limitations of Use: PARSABIV has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with chronic kidney disease who are not on hemodialysis and is not recommended for use in these populations.
- generic_name
- etelcalcetide
- product_names
- etelcalcetide
- ndc
- 55513-740, 55513-741, 55513-742, 55513-740-01, 55513-740-10, 55513-740-20, 55513-741-01, 55513-741-10, 55513-741-20, 55513-742-01, 55513-742-10, 55513-742-20
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en